Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997045405 - CYCLOPENTAN(EN)OIC ACID, 2-ALKENYL DERIVATIVES AS THERAPEUTIC AGENTS IN THE TREATMENT OF OCULAR HYPERTENSION

Publication Number WO/1997/045405
Publication Date 04.12.1997
International Application No. PCT/US1997/008123
International Filing Date 14.05.1997
Chapter 2 Demand Filed 15.12.1997
IPC
A61K 31/5575 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
5575having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
C07C 405/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
405Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
CPC
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
C07C 405/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
405Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Y10S 514/913
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
912Ophthalmic
913Glaucoma
Applicants
  • ALLERGAN SALES, INC. [US]/[US] (AllExceptUS)
  • GARST, Michael, E. [US]/[US] (UsOnly)
  • ROOF, Michael, B. [US]/[US] (UsOnly)
  • CHAN, Ming, F. [GB]/[US] (UsOnly)
  • WOODWARD, David, F. [GB]/[US] (UsOnly)
  • BURK, Robert, M. [US]/[US] (UsOnly)
  • GAC, Todd, S. [US]/[US] (UsOnly)
  • ANDREWS, Steven, W. [US]/[US] (UsOnly)
Inventors
  • GARST, Michael, E.
  • ROOF, Michael, B.
  • CHAN, Ming, F.
  • WOODWARD, David, F.
  • BURK, Robert, M.
  • GAC, Todd, S.
  • ANDREWS, Steven, W.
Agents
  • BARAN, Robert, J.
Priority Data
60/018,43528.05.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYCLOPENTAN(EN)OIC ACID, 2-ALKENYL DERIVATIVES AS THERAPEUTIC AGENTS IN THE TREATMENT OF OCULAR HYPERTENSION
(FR) DERIVES D'ACIDE CYCLOPENTAN(EN)OÏQUE, 2-ALCENYLE UTILISES EN TANT QU'AGENTS THERAPEUTIQUES DANS LE TRAITEMENT DE L'HYPERTENSION OCULAIRE
Abstract
(EN)
The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by structure formula (I): wherein the hatched segments represent $g(a) bonds; the wavy segments represent an $g(a) or $g(b) bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of -OR and N(R2); Y is = O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower radical having up to six carbon atoms; R is = O or hydroxy; m is = 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a $g(b) bond; n is 0, 2, 4 or 6, x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compounds of formula (I), e.g. a C1 and C6 alkyl ester derivative; or a pharmaceutical acceptable salt thereof.
(FR)
L'invention se rapporte à l'utilisation de prostaglandines modifiées à chaîne oméga en tant qu'agents hypotenseurs oculaires. La formule structurale (I) englobe les dérivés utilisés conformément à cette invention où les segments hachurés représentent des liaisons $g(a), les segments ondulés représentent une liaison $g(a) ou $g(b) et les segments en tirets représentent une liaison double ou simple; X est choisi dans le groupe constitué de -OR et de N(R2); Y est =O ou représente deux radicaux hydrogène, à condition que Y représente 2 radicaux hydrogène lorsque X est OH; R est l'hydrogène ou un radical alkyle inférieur possédant jusqu'à six atomes de carbone; R est =O ou hydroxy; m=0, 2, 4 ou 6, à condition que m ne soit pas égal à 4 lorsque le segment ondulé représente une liaison $g(b); n est égal à 0, à 2, à 4 ou à 6, x et y valent 0 ou 1, à condition que x soit égal à 1 quand y vaut 0 et que y soit égal à 1 quand x vaut 0; en variante, l'invention se rapporte à des dérivés d'ester 9, 11 et/ou 15 de la formule (I), par exemple, à un dérivé d'ester d'alkyle C1 et C6, ou encore à un sel pharmaceutiquement acceptable de ces dérivés.
Latest bibliographic data on file with the International Bureau